Cargando…

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial

There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yhim, Ho-Young, Yoon, Dok Hyun, Kim, Seok Jin, Yang, Deok-Hwan, Eom, Hyeon-Seok, Kim, Kyoung Ha, Park, Yong, Kim, Jin Seok, Kim, Hyo Jung, Suh, Cheolwon, Kim, Won Seog, Kwak, Jae-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463683/
https://www.ncbi.nlm.nih.gov/pubmed/32781541
http://dx.doi.org/10.3390/cancers12082192
_version_ 1783577189274353664
author Yhim, Ho-Young
Yoon, Dok Hyun
Kim, Seok Jin
Yang, Deok-Hwan
Eom, Hyeon-Seok
Kim, Kyoung Ha
Park, Yong
Kim, Jin Seok
Kim, Hyo Jung
Suh, Cheolwon
Kim, Won Seog
Kwak, Jae-Yong
author_facet Yhim, Ho-Young
Yoon, Dok Hyun
Kim, Seok Jin
Yang, Deok-Hwan
Eom, Hyeon-Seok
Kim, Kyoung Ha
Park, Yong
Kim, Jin Seok
Kim, Hyo Jung
Suh, Cheolwon
Kim, Won Seog
Kwak, Jae-Yong
author_sort Yhim, Ho-Young
collection PubMed
description There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX). Thirty-three patients with newly diagnosed primary breast DLBCL received six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and four fixed doses of IT-MTX (12 mg). The median age was 50 years (range, 29–75), and all patients were females. According to the CNS-International Prognostic Index, most patients (n = 28) were categorized as the low-risk group. Among the 33 patients, 32 completed R-CHOP, and 31 completed IT-MTX as planned. With a median follow-up of 46.1 months (interquartile range (IQR), 31.1–66.8), the 2-year progression-free and overall survival rates were 81.3% and 93.5%, respectively. Six patients experienced treatment failures, which included the CNS in four patients (two parenchyma and two leptomeninges) and breast in two patients (one ipsilateral and one contralateral). The 2-year cumulative incidence of CNS relapse was 12.5%. Although standard R-CHOP and IT-MTX without routine radiotherapy show clinically meaningful survival outcomes, this strategy may not be optimal for reducing CNS relapse and warrants further investigation.
format Online
Article
Text
id pubmed-7463683
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74636832020-09-02 First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial Yhim, Ho-Young Yoon, Dok Hyun Kim, Seok Jin Yang, Deok-Hwan Eom, Hyeon-Seok Kim, Kyoung Ha Park, Yong Kim, Jin Seok Kim, Hyo Jung Suh, Cheolwon Kim, Won Seog Kwak, Jae-Yong Cancers (Basel) Article There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX). Thirty-three patients with newly diagnosed primary breast DLBCL received six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and four fixed doses of IT-MTX (12 mg). The median age was 50 years (range, 29–75), and all patients were females. According to the CNS-International Prognostic Index, most patients (n = 28) were categorized as the low-risk group. Among the 33 patients, 32 completed R-CHOP, and 31 completed IT-MTX as planned. With a median follow-up of 46.1 months (interquartile range (IQR), 31.1–66.8), the 2-year progression-free and overall survival rates were 81.3% and 93.5%, respectively. Six patients experienced treatment failures, which included the CNS in four patients (two parenchyma and two leptomeninges) and breast in two patients (one ipsilateral and one contralateral). The 2-year cumulative incidence of CNS relapse was 12.5%. Although standard R-CHOP and IT-MTX without routine radiotherapy show clinically meaningful survival outcomes, this strategy may not be optimal for reducing CNS relapse and warrants further investigation. MDPI 2020-08-06 /pmc/articles/PMC7463683/ /pubmed/32781541 http://dx.doi.org/10.3390/cancers12082192 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yhim, Ho-Young
Yoon, Dok Hyun
Kim, Seok Jin
Yang, Deok-Hwan
Eom, Hyeon-Seok
Kim, Kyoung Ha
Park, Yong
Kim, Jin Seok
Kim, Hyo Jung
Suh, Cheolwon
Kim, Won Seog
Kwak, Jae-Yong
First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title_full First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title_fullStr First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title_full_unstemmed First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title_short First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
title_sort first-line treatment for primary breast diffuse large b-cell lymphoma using immunochemotherapy and central nervous system prophylaxis: a multicenter phase 2 trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463683/
https://www.ncbi.nlm.nih.gov/pubmed/32781541
http://dx.doi.org/10.3390/cancers12082192
work_keys_str_mv AT yhimhoyoung firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT yoondokhyun firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kimseokjin firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT yangdeokhwan firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT eomhyeonseok firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kimkyoungha firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT parkyong firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kimjinseok firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kimhyojung firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT suhcheolwon firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kimwonseog firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial
AT kwakjaeyong firstlinetreatmentforprimarybreastdiffuselargebcelllymphomausingimmunochemotherapyandcentralnervoussystemprophylaxisamulticenterphase2trial